Since the 1950s the U.S. military has used intramuscular injections of benzathine penicillin G (BPG) to control outbreaks of respiratory disease. In an effort to find an alternative prophylaxis, a randomized field trial was conducted among 1,016 male U.S. Marine trainee volunteers at high risk for respiratory disease. Participants were evaluated for evidence of acute respiratory infection by serological tests on pretraining and posttraining sera (63 days apart). Oral azithromycin prophylaxis (500 mg/w) outperformed BPG, preventing infection from Streptococcus pyogenes (Efficacy [E] Å 84%; 95% confidence interval [CI], 63% -93%), Streptococcus pneumoniae (E Å 80%; 95% CI, 50% -92%), Mycoplasma pneumoniae (E Å 64%; 95% CI, 25% -83%), and Chlamydia pneumoniae (E Å 58%; 95% CI, 15% -79%) in comparison with results in a no-treatment group. Azithromycin group subjects reported few side effects and less respiratory symptoms than the BPG and no-treatment groups. According to serological tests, oral azithromycin is an effective alternative prophylaxis to BPG for military populations.
Both in the preantibiotic era and in recent years, acute respiever, reports of penicillin tolerance among S. pyogenes isolates [12 -14] and penicillin resistance [15] among S. pneumoniae ratory infections have been frequent causes of outpatient and inpatient morbidity among adults in the United States, espeisolates threaten military preventive strategies. At least one authority has suggested that penicillin resistance among S. pyocially military personnel [1 -6] . Studies of respiratory disease in military personnel have led to a number of vaccine and genes isolates is likely to occur [16] . The emergence of more virulent S. pyogenes strains [17, 18] and their severe disease antibiotic prophylactic therapies [4, 5] . These interventions have been proven effective in both civilian and military populamanifestations [19 -21] are further causes for concern. Easily administered and safe alternative therapies to BPG tions.
Since the 1950s, intramuscular injections of benzathine peniare needed, particularly for persons allergic to penicillin [22] . Recently, low-dose oral erythromycin has been used with some cillin G (BPG) have been used to prevent Streptococcus pyogenes infections [7 -10] and to combat Streptococcus pneusuccess, although the twice-daily dosing requirements and gastrointestinal side effects have caused compliance problems moniae pneumonia epidemics [11] among new military personnel. Generally, BPG has been safe and effective; how- [22 -23] . Ideally, new prophylactic therapies should be effective in preventing other common causes of upper and lower respiratory tract infection among military populations, such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Haemophilus influenzae [24 -26] . Table 1 . Enrollment characteristics of study subjects assigned to provides 9 weeks of combat training to new Marines after they the three treatment groups for prophylaxis against acute respiratory complete 11 weeks of initial recruit training in San Diego.
infection.
Training takes place in companies of Ç320 men and involves many stresses, including exhaustive tests of physical endur- Before reporting to Infantry Training School, many study participants had received pneumococcal and adenovirus (types 4 and 7) vaccines during their recruit camp training 3 -4 months ing, or physical-examination findings consistent with respiratory infection. These persons were further evaluated with throat earlier (table 1). Vaccine data were abstracted from the records of the Marine Corps Recruit Depot Medical Clinic (San Diego).
swab sampling and nasopharyngeal aspiration with use of 3 mL of a sterile solution wash and a Delee suction catheter with Both upon enrollment and at the end of training (median, 63 days later), study participants completed a questionnaire, trap. If the nasopharyngeal aspirate was inadequate, a calcium alginate swab was used to collect a nasopharyngeal culture donated 15 mL of blood, and permitted a throat culture. The enrollment questionnaire collected demographic information specimen. A research assistant also administered a clinical evaluation questionnaire that collected information on the duration and recent data about symptoms. The posttraining questionnaire requested information regarding symptoms of respiratory illof the current illness, physical examination findings, whether chest radiography was performed, diagnosis, antibiotic regimen ness and also asked subjects if they had sought treatment for respiratory illness since enrolling in the study. For subjects in prescribed, and medical conditions contributing to the current illness. the azithromycin group, additional information was requested, including the number of doses taken and reasons for missing any doses.
Laboratory Studies
Study subjects were considered to have an acute respiratory infection if they visited military sick call with any of the followAll laboratory personnel were blinded with regard to specimen linkage with treatment groups. ing: a sore or inflamed throat, a cough, difficult or rapid breath-/ 9c43$$ja55
11-25-97 11:24:14 cida UC: CID Streptococcus identification. Throat and nasal swabs were IgM titer from negative to positive was considered serological evidence of acute infection. plated onto a 5% sheep blood agar plate within 4 hours of sample collection and incubated in 5% CO 2 at 35ЊC. Plates Antibodies to pneumolysin (specific for S. pneumoniae), H. influenzae, and Moraxella catarrhalis were also measured were examined at 24 and 48 hours for b-and/or a-hemolytic colonies, which were subcultured for isolation. Isolation and by EIA [37, 38] . These results were recorded in optical density units on a continuous scale (not a titered dilution scale). As identification of S. pyogenes and S. pneumoniae were accomplished with standard procedures [27, 28] . All b-hemolytic, per previous published reports, a twofold (100%) rise in IgG titer (pretraining to posttraining) against pneumolysin was concatalase-negative, gram-positive cocci were screened for streptococcal antigens (Lancefield groups A, B, C, F, G; Difco, sidered evidence of recent infection [37, 39] . Similarly, a 2.5-fold increase in IgG titer was considered evidence of recent Detroit), and biochemical confirmation was done with the API 20S kit (bioMèrieux Vitek; Hazelwood, MO). a-Hemolytic infection in the EIAs for H. influenzae and M. catarrhalis [38] . Nucleic acid detection for C. pneumoniae. Nasopharyngeal streptococci that were gram-positive and catalase-negative and had a positive optochin disk reaction were presumed to be aspirates were evaluated for C. pneumoniae with use of PCR. Nucleic acid was extracted from 400 mL of aspirate by means S. pneumoniae. Biochemical confirmation was done by bilesolubility evaluation and with use of the API 20S kit.
of QIAamp DNA isolation columns (Quiagen, Chatsworth, CA), as described by the manufacturer. Twenty mL of eluate Streptococcus antimicrobial testing. The MICs of azithromycin, erythromycin, penicillin, and cefotaxime against S. pyofrom each column was used for specific PCR amplification of C. pneumoniae DNA. Positive controls consisting of genes and S. pneumoniae were determined with the Etest (AB Biodisk, Solna, Sweden). Isolates were resuspended in 1 mL of C. pneumoniae organisms and several negative controls were included in each assay. sterile PBS. Suspensions were inoculated onto Mueller-Hinton sheep blood agar plates (Hardy Diagnostic; Santa Maria, CA), Primers used for C. pneumoniae amplification were CpnA and PTW51, which resulted in a 369-bp amplified fragment and after 10 -15 minutes of drying, the Etest strips were applied. Susceptibility plates were incubated at 35ЊC under 5% [40] . The PCR reaction was performed in 10 mM of Tris (pH, minutes and 95ЊC for 5 minutes, followed by 40 cycles of 94ЊC for 10 seconds, 58ЊC for 15 seconds, and 72ЊC for 35 seconds. Serological testing. Sera were tested for S. pyogenes antibodies by the antistreptolysin O (ASO) and the antideoxyriboFollowing amplification, PCR products were detected in a liquid hybridization format using a 32 P-labeled C. pneumoniaenuclease B microtitration (DNAse B) procedures, with use of a 0.10-log scale [31, 32] . Bacto-Streptolysin O reagent (Difco), specific probe, PTW50 [40] . Streptonase-B reagent and enzyme (Wampole; Cranbury, NJ), and Bacto-Streptolysin O buffer dried (Difco) were prepared Statistical Analyses and used as described by the manufacturers. A two-dilution rise (0.2-log change) in titer (pretraining to post-training) of Potential risk factors for the various clinical and laboratory outcomes were evaluated for relative risk. Confidence intervals either antigen was considered evidence of recent S. pyogenes infection [33] .
about relative risk calculations were determined by the Taylor series method [41] . Efficacy calculations were made with the C. pneumoniae -specific IgG, IgA, and IgM were measured by the microimmunofluorescence test, with elementary bodies following formula: of C. pneumoniae Kajaani 6 as the antigen [34] . Sera were Efficacy (E) Å 1 0 relative risk (RR). tested in serial twofold dilutions from 1:32 for IgG and 1:16 for IgA to the endpoint. IgM antibodies were first screened at a dilution of 1:16, and positive sera were retested after treatResults ment with goat antibody to human IgG antibody (Gullsorb; Gull
Study Participation
Laboratories, Salt Lake City). A positive, acute C. pneumoniae infection was defined as a fourfold rise in IgG or IgA titer Written informed consent was obtained from 1,102 Marines (95% participation). Of these, 1,038 (94%) were followed (with enrollment IgM õ1:16) or a pretraining to posttraining change in IgM titer from õ1:16 to §1: 16 [35] .
throughout their Infantry Training School experience. Upon enrollment, subjects assigned to the three treatment arms were EIAs for IgM and IgG on paired sera were performed with use of a whole-cell lysate of M. pneumoniae, as previously similar with regard to distribution of age, race, home of record, vaccine history, colonization with streptococci, and recent described [36] . Endpoint titration was performed on every serum, and a fourfold rise in IgG or IgM titer or a change in acute respiratory disease symptoms ( Clinical evaluations, self-reported symptoms, posttraining appetite (n Å 3), ''feeling hot'' (n Å 3), and dizziness (n Å 2).
colonization with streptococci, and serological findings were There was no statistical difference between the three study evaluated by treatment group (table 2) . Azithromycin group groups in reports of §1 day of diarrhea. subjects experienced fewer hospitalizations for pneumonia and fewer medical visits for acute respiratory infection (table 2) than did subjects in the other two groups; however, these differ-
Evidence of Clinical Respiratory Disease
ences were not statistically significant. To reduce potential confounding, three subjects who had Serological evidence of infection. Azithromycin group sub-õ55 or ú100 days of training were excluded from analyses.
jects were less likely than the no-treatment group subjects to An additional 19 azithromycin group subjects were excluded have serological evidence of infection with 1 or more bacterial because they missed §1 week of therapy. Despite prophylactic pathogens (RR Å 0.38; 95% CI, 0.28 -0.51). Azithromycin interventions among two-thirds of the 1,016 remaining subprotected subjects against infection from a number of specific jects, considerable evidence of clinical respiratory disease was apparent.
Overall, 730 (71.9%) of the Marines had evidence of acute from the BPG group) were hospitalized because of radiographic evidence of pneumonia. The no-treatment patient had received * Patients had clinical evidence of an acute respiratory infection or they reported that they visited the medical clinic with a ''breathing illness. '' both adenovirus and pneumococcal vaccines during recruit † Percentage of subjects whose enrollment pharyngeal cultures were negative training. His sputum gram stain result was not reported, but he for this agent.
had serological evidence of C. pneumoniae infection. Neither ‡ Due to exhaustion of sera, some assays were run on fewer pairs of sera, but every test was run on at least 94% of serum pairs.
patient from the BPG group with pneumonia had received / 9c43$$ja55 11-25-97 11:24:14 cida UC: CID bacterial pathogens: S. pyogenes, per ASO (E Å 84%; 95% (RR Å 6.91; 95% CI, 3.8 -12.7). Neither the azithromycin nor the BPG was protective against new colonization with CI, 63% -93%); S. pyogenes, per DNAse B (E Å 70%; 95% CI, 44% -84%); S. pneumoniae (E Å 80%; 95% CI, 50% -S. pneumoniae. For all S. pyogenes (n Å 79) and S. pneumoniae (n Å 24) 92%); M. pneumoniae (E Å 64%; 95% CI, 25% -83%); and C. pneumoniae (E Å 58%; 95% CI, 15% -79%) (table 3). In pharyngeal isolates (from pretraining, acute respiratory disease episodes, and posttraining) the Etest MICs of azithromycin, contrast, the BPG group had serological evidence of protection against only S. pyogenes by the ASO assay (E Å 45%; 95% erythromycin, penicillin, and cefotaxime were well under resistance breakpoints. CI, 10% -66%). The pneumococcal vaccine, as shown by the pneumolysin serological test, offered no protection against S. pneumoniae infection (E Å 3%; 95% CI, 0 -43%). When Discussion the 82 subjects who sought medical care for respiratory illness and permitted nasopharyngeal aspiration were considered, This randomized field trial of two prophylactic treatments was conducted in a population of young adult males at high risk those with PCR evidence of C. pneumoniae infection were more likely to also show serological evidence of infection for acute respiratory disease. Five years earlier, this training population suffered the largest S. pneumoniae pneumonia epi-(RR Å 4.7; 95% CI, 1.5 -14.9) than those without PCR evidence.
demic recorded since the development of antibiotics [11] . This population also had the highest pneumonia-related hospitalizaSymptoms reported. Azithromycin group subjects were less likely than BPG recipients to report §1 day of respiratory tion rate among Navy and Marine Corps personnel [4] . During several recent winters, military public health officials had emsymptoms during training (RR Å 0.79; 95% CI, 0.70 -0.90). Fewer subjects in the azithromycin group reported a §1-day ployed mass BPG and pneumococcal vaccine interventions to control epidemics at this site. history of cough (table 2) (RR Å 0.68; 95% CI, 0.57 -0.81), fever (RR Å 0.71; 95% CI, 0.54 -0.93), sore throat
Despite an intervention among two-thirds of the study population, 72% of the trainees had evidence of a clinically signifi-(RR Å 0.78; 95% CI, 0.65 -0.94), and breathing illness (RR Å 0.67; 95% CI, 0.45 -0.98). In contrast, the BPG treatcant respiratory infection, yet only 18% of the ill trainees sought medical care. This is consistent with the medical literament offered no reduced risk of posttraining reporting of any respiratory symptom.
ture concerning military trainees. In 1962, researchers at the Naval Training Center in Great Lakes, Illinois, reported that Streptococcal pharyngeal colonizations. Compared with the no-treatment group, azithromycin protected subjects with only 12% -14% of recruits with clinical respiratory disease sought medical attention [42] . Similarly, it was noted in 1989 no throat-culture evidence of S. pyogenes upon enrollment from having an S. pyogenes -positive throat culture at training's end that only 36% of Marine Corps trainees sought medical attention despite reporting a sore throat for §6 hours and having (table 2) (E Å 96%; 95% CI, 69% -99%). The BPG group's corresponding efficacy was 42% (95% CI, 0 -69%). Newly serological evidence of S. pyogenes infection [22] . This reluctance to seek medical attention makes evaluating public health colonized study subjects were more likely to have ASO serological evidence of S. pyogenes infection than were subjects interventions difficult in military populations. Exclusive measurement of clinical outcomes will underestiwho were not newly colonized at the end of training mate disease incidence and may misrepresent other disease characteristics. In addition, it is difficult in this clinical setting izations for pneumonia in the military are reported without a specific agent being identified [4] . Intensive efforts to define a Efficacy, % (95% CI)
pathogen fail in 50% of instances [4] . mycin should be followed with routine surveillance for azithromycin resistance. With these problems, azithromycin is not It was interesting that pneumococcal vaccine failed to protect the recipients from serologically evident S. pneumoniae infeclikely to immediately supplant BPG for routine prophylactic therapy in military training populations. However, it may have tion. This poor efficacy might be explained by endemic strains that are distinct from the strains used to prepare the 23-valent a role in certain acute respiratory epidemics, especially when the suspected etiologic agents are not likely to respond to BPG. vaccine. However, serotyping studies of the S. pneumoniae isolates were not performed.
In summary, 500 mg weekly of oral azithromycin and 1.2 million units of intramuscular BPG were compared with no The poor performance of BPG in this setting is likely explained by the 63-day period of study. The effect of BPG treatment as prophylactic agents against a number of bacterial respiratory pathogens. Over their 63 days of military training, against S. pyogenes is thought to last for 1 -4 weeks for an individual recipient [44 -47] ; however, applying the antibiotic 1,016 young-adult male study subjects had considerable clinical and serological evidence of acute respiratory infection. Oral uniformly in a single dose to a large, confined population may reduce the endemnicity of the pathogen and thereby have a azithromycin recipients reported fewer respiratory symptoms and were protected from pharyngeal colonization and infection more prolonged protective effect. Such is the strategy employed by both the U.S. Army and U.S. Air Force in protecting their with S. pyogenes. Azithromycin recipients also were protected from infection with S. pneumoniae, M. pneumoniae, and recruit trainees for 6 -8 weeks by giving them a single BPG injection when they enter training camp [48, 49] .
C. pneumoniae. BPG recipients were only partially protected from S. pyogenes infection. Weekly oral azithromycin was well This strategy also is used in combating Navy and Marine Corps epidemics of acute respiratory disease that occur outside tolerated and may be an effective alternative to BPG prophylaxis in preventing bacterial respiratory infections among miliof recruit training [11] . Hence, administration of a single dose of BPG to Infantry Training School entrants was used in this tary populations. field trial as the standard prophylactic intervention for this postrecruit training population. A previous report suggested
